Focus: Purdue Pharma is a specialty pharmaceutical company headquartered in Stamford, CT, focused on small molecule therapeutics in neurology and pain management. The company derives 94% of revenue from OxyContin, making it a highly concentrated, legacy-driven business.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Purdue Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Purdue Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Purdue Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Extended-release tramadol formulation with documented clinical efficacy but minimal market presence.
Opioid antagonist with longer duration than naloxone; positioned for expansion as overdose crisis response therapy.
CNS stimulant for ADHD with extended-release formulation; peak lifecycle status but LOE approaching 2038.
Sleep maintenance agent facing LOE in 2029; limited commercial impact.
ANDA-approved opioid antagonist in post-LOE phase; potential indication expansion into depression noted.
8 discontinued, 1 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
+2 more